{
  "company": "CIPLA",
  "report_date": "November 06, 2019",
  "filename": "CIPLA_transcript_Nov_2019.pdf",
  "quarter": "Q2",
  "fiscal_year": "2020",
  "management_team": [
    "MR. UMANG VOHRA - - M.D. & GLOBAL CEO, CIPLA",
    "MR. KEDAR UPADHYE - - GLOBAL CFO, CIPLA",
    "MR. NAVEEN BANSAL - INVESTOR RELATIONS TEAM,",
    "UMANG VOHRA - - M.D. & GLOBAL CEO, CIPLA",
    "KEDAR UPADHYE - - GLOBAL CFO, CIPLA",
    "NAVEEN BANSAL - INVESTOR RELATIONS TEAM,"
  ],
  "moderator": "MR",
  "analysts": [
    {
      "name": "Neha Manpuria",
      "firm": "JP Morgan Chase \n& Co"
    },
    {
      "name": "Anubhav Agarwal",
      "firm": "Credit \nSuisse"
    },
    {
      "name": "Nimesh Meheta",
      "firm": "Research Delta \nAdvisors"
    },
    {
      "name": "Nitin Agarwal",
      "firm": "IDFC Securities \nLtd"
    },
    {
      "name": "Sameer Baisiwala",
      "firm": "Morgan \nStanley"
    },
    {
      "name": "Krishnendu Saha",
      "firm": "Quantum Mutual \nFund"
    },
    {
      "name": "Aditya Khemka",
      "firm": "DSP Mutual Fund"
    },
    {
      "name": "Harith Ahmed",
      "firm": "Spark Capital"
    },
    {
      "name": "Shyam Srinivasan",
      "firm": "Goldman Sachs"
    },
    {
      "name": "Charulata Gaidhani",
      "firm": "Dalal & \nBroacha Stock Broking Pvt"
    },
    {
      "name": "Bharat Seth",
      "firm": "Quest Investment \nAdvisors Pvt"
    },
    {
      "name": "Damyanti Kirai",
      "firm": "HSBC"
    },
    {
      "name": "Vishal Manchanda",
      "firm": "Nirmal Bang Securities Pvt"
    }
  ],
  "qa_segments": [],
  "key_financial_metrics": {
    "growth_percentage": "10",
    "increase_percentage": "7",
    "ebitda_margin_percentage": "21",
    "ebitda_inr_crores": "909"
  },
  "business_highlights": [
    "partnership with Novartis for marketing and distribution of the Ultibro \nBreezhaler.",
    "partnership with Novartis \neffective October 1st to market the respiratory portfolio in the Australian market.",
    "partnership with Novartis, we \nare working towards bringing our EM biosimilar franchise to fruition with Pegfilgrastim filed in \nMalaysia and approval received for clinical trials of Bevacizumab in Algeria.",
    "partnership with another company on a fairly significant MDI.",
    "acquired Mirren portfolio growing strongly, Cipla is the third largest player in the OTC \nmarket capturing a market share of 6."
  ],
  "extraction_metadata": {
    "extraction_date": "2025-08-03T01:08:54.895054",
    "source_file": "data\\cipla\\CIPLA_transcript_Nov_2019.pdf",
    "text_length": 51445,
    "extraction_method": "PyMuPDF + Regex parsing + Filename analysis"
  }
}